1.
215 Alden Lane · Cleveland, Ohio · 44143
Phone 216.965.5134 · Email koj2@ccf.org; jennifersusanko@yahoo.com
Jennifer Susan Ko
Education and Training
2014 – 2015 Fellowship
Dermatopathology, Cleveland Clinic, Cleveland, OH
2010 – 2014 Residency
Anatomic and Clinical Pathology, Cleveland Clinic
2005 – 2010 Doctor of Philosophy
Case Western Reserve University, Cleveland, OH
2004 – 2010 Clinical Scholar
Experimental Therapeutics in Oncology and Immunology,
Cleveland Clinic
2003 – 2004 Internship
General Internal Medicine, Cleveland Clinic
1999 – 2003 Doctor of Medicine
Northeastern Ohio Universities College of Medicine
(NEOUCOM), Rootstown, Ohio
1997 – 1999 Bachelor of Science
University of Akron, Akron, Ohio
Certifications and Licenses
State Medical Board of Ohio
License Number 35.087166
American Board of Pathology, Specialty Certification, Anatomic and Clinical Pathology
Date July 30, 2014
American Board of Pathology, Subspecialty Certification, Dermatopathology
Date September 28, 2015
Honors and Awards
Fellowship
• 1st
Place Best Resident/Fellow Poster Presentation at the American Society of
Dermatopathology 51st
Annual Meeting; November 6th
-9th
2015; Chicago Il, USA.
• Scholarship, World Congress of Dermatology 23rd
Annual Meeting, June 8th
-13th
2015;
Vancouver, Canada.
• Gold Presentation Winner, Annual Research Day in the Department of Dermatology,
Cleveland Clinic; May 19th 2015; Cleveland, Ohio.
• 1st Place Best Resident/Fellow Presentation, Cleveland Society of Pathology; May 27th;
Cleveland, Ohio.
Residency

2.
• 1st
Place Best Resident/Fellow Poster Presentation at the American Society of
Dermatopathology 50th
Annual Meeting; October 10th
-13th
2014; Washington DC, USA.
Graduate (Doctoral)
• Fellowship Award, Moffitt Cancer Center, Molecular Targets for Cancer Therapy:
Regulatory Myeloid Suppressor Cells in Health and Disease
• Summa cum laude graduate
Medical School
• Alpha Omega Alpha (AOA), medical honor society
• NEOUCOM Pasteur Award, for excellence in microbiology, immunology, and infectious
disease
• American Medical Women’s Association Janet M. Glascow Memorial Achievement
Citation
Undergraduate
• Presidential Scholarship
• Summa cum laude graduate
Research and Other Experience
1/2005 – 6/2010 Graduate Student (Doctoral)
James H. Finke
Cleveland Clinic Lerner Research Institute, Dept. of Immunology; and
Case Western Reserve University, Dept. of Pathology
8/2006 – 6/2010 Myeloid-derived Suppressor Cell accumulation in tumor-bearing
hosts
1/2005 - 8/2006 Tumor-secreted ganglioside suppression of immune cell function
7/2004 – 6/2010 Clinical Scholar- Experimental Therapeutics in Melanoma
Ernest C. Borden
Cleveland Clinic Taussig Cancer Institute
Summer 2001 Research Elective
John J. Docherty
NEOUCOM Dept. of Microbiology and Immunology
9/2000 – 5/2001 Teaching Assistant, Biochemistry
Phillip W. Westerman, Professor Emeritus
NEOUCOM Dept. of Biochemistry
Publications
Ko JS, Prieto VG, Elson P, Vilain RE, Pulitzer M, Scolyer RA, Reynolds JP, Piliang M, Ernstoff
MS, Gastman M, Billings SD. "Histologic pattern of Merkel cell carcinoma sentinel lymph node
metastasis improves stratification of Stage III patients" Accepted for publication in Modern
Pathology.
Ko JS, Billings SD. “Diagnostically challenging epithelioid vascular tumors.” Surg Pathol Clin.
2015 Sep;8(3):331-51.
Jennifer Ko 2/10

3.
Wu L, Zepp J, Ko JS, Zhao J, Chen X, Gu G, Towne J, Ouyang W, Sen G, Stark G, Su B,
Gastman B, Liu C, Li X. “A novel IL-17 signaling pathway through the TRAF4-MEKK3-ERK5
axis for keratinocyte proliferation and tumorigenesis.” Accepted at J Exp Med.
Mahata B, Biswas S, Rayman P, Chahlavi A, Ko J, Bhattacharjee A, Li YT, Li Y, Das T,
Sa G, Raychaudhuri B, Vogelbaum MA, Tannenbaum C, Finke JH, Biswas K. "GBM
Derived Gangliosides Induce T Cell Apoptosis through Activation of the Caspase
Cascade Involving Both the Extrinsic and the Intrinsic Pathway." PLoS One. 2015 Jul
30;7:e0134425.
Ko JS, Billings SD, Lanigan CP, Buehler D, Fernandez AP, Tubbs RR. “Fully Automated Dual-
Color Dual-Hapten Silver In-Situ Hybridization Staining for MYC Amplification: a Diagnostic
Tool for Discriminating Secondary Angiosarcoma” J Cutan Pathol. 2014, 41(3): 286-92.
Finke JH, Rayman PA, Ko JS, Bradley JM, Gendler SJ, Cohen PA. “Modification of the Tumor
Microenvironment as a Novel Target of Renal Cell Carcinoma Therapeutics.” Cancer J 2013
19(4): 353-64.
Ko JS, Falzarano SM, Walker E, Streator-Smith K, Stephenson AJ, Klein E, Magi-Galluzzi C.
“Prostate cancer patients older than 70 years treated by radical prostatectomy have higher
biochemical recurrence rate than their matched younger counterpart.” Prostate 2013, 73(8): 897-
903.
Ko JS, Fernandez AP, Anderson KA, Burdick LM, Billings SD, Procop GW, McMahon JT,
Bergfeld WF, Piliang MP. “Morphologic mimickers of Cryptococcus occurring within
inflammatory infiltrates in the setting of neutrophilic dermatoses: a series of 3 cases highlighting
clinical dilemmas associated with a novel histologic pitfall.” J Cutan Pathol 2013, 40(1): 38-45.
Wang C, Wu L, Bulek K, Martin B, Zepp J, Kang Z, Liu C, Herjan T, Misra S, Carman J, Gao J,
Dongre A, Han S, Bunting K, Ko JS, Xiao H, Kuchroo V, Ouyang W, Li X. “The psoriasis-
associated D10N variant of the adaptor Act1 with impaired regulation by the molecular
chaperone hsp90.” Nat Immunol. 2013, 14(1): 72-81.
Cohen PA, Ko JS, Storkus WJ, Spencer CD, Bradley JM, Gorman JE, McCurry DB, Zorro-
Manrique S, Dominguez AL, Pathangey LB, Rayman PA, Rini BI, Gendler SJ, and Finke JH.
“Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent
hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic
escape.” Immunol Invest. 2012, 41(6-7): 680-710.
Martin ST, Ko JS, Plesec TP, Ananthakrishnan L, Remzi FH. “Colonic duplication mimicking
fistulizing Crohn’s Colitis.” Inflamm. Bowel Dis. 2011, 17(8):E103-5.
Finke J, Ko J, Rini B, and Cohen P. “TKI and the Immune Response: Is there Potential for
Combination Therapy?” Kid Cancer J 2011, 9(1): 23-34.
Jennifer Ko 3/10

4.
Raychaudhuri B, Rayman P, Ireland J, Ko J, Rini BI, Borden E, Garcia J, Vogelbaum MA, and
Finke J. “Myeloid derived suppressor cell accumulation and function in patients with newly
diagnosed glioblastoma.” Neuro. Oncol. 2011, 13(6):591-599.
Finke J, Ko J, Rini B, Rayman P, Ireland J and Cohen P. “MDSC as a mechanism of tumor
escape form sunitinib mediated anti-angiogenic therapy.” Int Immunopharmacol 2011,
11(7):856-861.
Bose A, Taylor JL, Alber S, Watkins SC, Garcia JA, Rini, BI, Ko JS, Cohen PA, Finke JH and
Storkus WJ. “Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor
immunity in concert with specific vaccination.” Int. J. Cancer 2011, 129(9): 2158-70.
Ko J, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, Rini B, Cohen P, Finke J. “Direct
and differential suppression of MDSC subsets by sunitinib is compartmentally constrained.”
Cancer Res. 2010, 70(9): 3526-36.
Seliger B, Massa C, Rini B, Ko J, Finke J. “Antitumor and immune-adjuvant activities of
protein-tyrosine kinase inhibitors.” Trends Mol. Med. 2010, 16(4): 184-92.
Ko J, Zea A, Rini B, Ireland J, Elson P, Cohen P, Golshayan A, Rayman P, Wood L, Garcia J,
Driecer R, Bukowski R, Finke J. “Sunitinib mediates reversal of myeloid-derived suppressor
cell accumulation in renal cell carcinoma patients.” Clin. Cancer Res. 2009, 15(6): 2148-57.
Ko J, Bukowski R, Finke J. “Myeloid-derived suppressor cells: a novel therapeutic target.”
Curr. Oncol. Rep. 2009, 11(2): 87-93.
Biswas S, Richmond A, Biswas K, Ko J, Ghosh S, Simmons M, Rayman P, Rini B, Gill I,
Tannenbaum C, Finke J. “Elevated levels of select gangliosides in T cells from renal cell
carcinoma patients is associated with T cell dysfunction.” J. Immunol. 2009, 183(8): 5050-8.
Salas R, Ko J, Finke J. Immunobiology of metastatic renal cell carcinoma. In: Rini B and
Campbell S (Eds.) Renal Cell Carcinoma. Hamilton, Ontario: BD Becker Inc; 2008: 167-179.
Docherty JJ, Smith JS, Fu MM, Stoner T, Booth T. “Effect of topically applied resveratrol on
cutaneous herpes simplex virus infections in hairless mice.” Antiviral Res. 2004, 61(1): 19-26.
Smith JS, Brodell RT. “Improved therapy for atopic eczema. New immunomodulators clear the
rash with few side effects.” Postgrad Med 2004, 115(1):35-7.
Abstracts and Posters
Ko JS, Gastman B, Bergfeld W. A 1-year pathology review of facial allotransplantation
resulting from granulomatosis with polyangiitis and malignant pyoderma. The American
Society of Dermatopathology 52nd Annual Meeting; 2015 October 8-11; San Francisco,
CA.
Ko JS, Daniels B, Emanuel P, Billings SD. Breaking bad dogma: the diversity of
spindle cell lipomas in women. The American Society of Dermatopathology 52nd
Annual Meeting; 2015 October 8-11; San Francisco, CA.
Jennifer Ko 4/10

5.
Ko JS, Billings SD. Utility of Sox10 immunohistochemical staining to distinguish
non-ossifying fibromyxoid tumor from epithelioid schwannoma. The American Society
of Dermatopathology 52nd Annual Meeting; 2015 October 8-11; San Francisco, CA.
Minca E, Billings SD, Ko JS. Significance of epidermal mitoses in challenging
melanocytic proliferations. The American Society of Dermatopathology 52nd Annual
Meeting; 2015 October 8-11; San Francisco, CA.
Feasel P, Billings B, Fernandez A, Piliang M, Bergfeld W, Ko JS. Can direct
immunofluorescence (DIF) testing of bullous disorders be streamlined? – a single
institution experience with bullous pemphigoid (BP). The American Society of
Dermatopathology 52nd Annual Meeting; 2015 October 8-11; San Francisco, CA.
Uberti G, Billings S, Goldblum J, Ko JS. Desmoplastic Granular Cell Tumor, a Rare
Variant with Unique Diagnostic Challenges. Duel in Dermatopathology. The American
Society of Dermatopathology 52nd Annual Meeting; 2015 October 8-11; San Francisco,
CA.
DiCarlo C, Uchin J, Piliang M, Ko JS. Longitudinal Biopsies over Many Years
Culminating in a Rare and Instructive Case of Atypical Galli-Galli Disease. Duel in
Dermatopathology. The American Society of Dermatopathology 52nd Annual Meeting;
2015 October 8-11; San Francisco, CA.
McHugh K, Tetzlaff M, Billings S, Ko JS. Ultra-late (32 years) recurrence of atypical
Spitz tumor as pleomorphic melanoma with a favorable immune signature: non-
experimental evidence of immune equilibrium. The American Society of
Dermatopathology 52nd Annual Meeting; 2015 October 8-11; San Francisco, CA.
Nomani, L, Billings, SD, Naous, R, Ko JS. Neurotropic desmoplastic melanoma with an
epithelioid façade masquerades as epithelioid schwannoma. The American Society of
Dermatopathology 52nd Annual Meeting; 2015 October 8-11; San Francisco, CA.
Ko JS, Prieto VG, Vilain R, Scolyer R, Reynolds JP, Billings SD. Histologic Pattern of
Merkel Cell Carcinoma Sentinel Lymph Node Metastasis and Patient Immune Status
Significantly Impacts Disease Outcome. United States and Canadian Academy of
Pathology Annual Meeting; 2015 March 21-27; Boston, MA, USA.
Ko JS, Billings SD. Significance of histologic pattern of Merkel cell carcinoma (MCC)
metastasis in sentinel lymph node biopsies (SLNBx) and patient immune status in disease
outcome. The American Society of Dermatopathology 51st Annual Meeting; 2014 November 6-
9; Chicago, Il.
Ko JS, Miner A, Bergfeld W. Ectopic Paget’s disease of the neck associated with underlying
cutaneous apocrine carcinoma. The American Society of Dermatopathology 51st Annual
Meeting; 2014 November 6-9; Chicago, Il.
Ko JS, Cheah A, Billings SD. Life on the edge: A series of two cases of amelanotic spindle cell
melanoma with sarcomatoid dedifferentiation. The American Society of Dermatopathology 51st
Annual Meeting; 2014 November 6-9; Chicago, Il.
Jennifer Ko 5/10

6.
Ko JS, Rayman P, Yang Y, Gopalan B, Finke F. Differential gene expression in G-
MDSC and neutrophils from renal cell carcinoma patients. Society for Immunotherapy
of Cancer 29th Annual Meeting: 2014 November 8-10; National Harbor, MD, USA.
Ko JS, Rayman P, Borden EC, Obery D, Lindner D, Finke JH. Proangiogenic Neutrophilic-
Myeloid-Derived Suppressor Cells Emerge Via Two Parallel Pathways in Renal Cell Carcinoma
and Melanoma. Society for Immunotherapy of Cancer 28th
Annual Meeting: 2013 November 8-
10; National Harbor, MD, USA.
Obery DR, Rayman PA, Yang Y, Ko JS, Finke JH. Neutrophils from renal cell carcinoma
patients show increased expression of immunosuppressive and angiogenic gene profile. Society
for Immunotherapy of Cancer 28th Annual Meeting: 2013 November 8-10; National Harbor,
MD, USA.
Ko JS, Rayman P, Borden EC, Lindner D, Finke J. Neutrophilic myeloid-derived suppressor
cells and conventional neutrophils suppress t-cells and promote angiogenesis in malignant
melanoma. The American Society of Dermatopathology 50th
Annual Meeting; 2013 October 10-
13; Washington DC, USA.
Ko JS and Fernandez AP. Multicentric reticulohistiocytosis: case report and review of a
mechanistically and therapeutically elusive disease. The American Society of Dermatopathology
50th
Annual Meeting; 2013 October 10-13; Washington DC, USA.
Ko JS, Kyei A, Keller E, Piliang MP. Bullous acrodermatitis enteropathica with atypical
histopathology: an increasingly important diagnostic consideration. The American Society of
Dermatopathology 50th
Annual Meeting; 2013 October 10-13; Washington DC, USA.
Ko JS and Billings SD. Perineuriomatous nevus: a newly recognized variant. 16th
Joint
Meeting of the International Society of Dermatopathology; 2012 February 27-March 1; Miami,
Fl, USA.
Ko JS, Fernandez AP, Anderson K, Burdick LM, Billings SD, Procop GW, McMahon JT,
Bergfeld WF, and Piliang MP. Morphologic mimicry of Cryptococcus in the setting of
neutrophilic dermatoses: a series of 3 cases highlighting a novel histologic pitfall. The American
Society of Dermatopathology 49th
Annual Meeting; 2012 October 11-14; Chicago, Il., USA.
Ko JS, SD Billings, L Durkin, Lin J, W-L Wang, AJ Lazar, ED His. Immunohistochemical
staining for p-ERK: A potential screening tool for BRAF mutations in melanoma. United States
and Canadian Academy of Pathology 101st
Annual Meeting; 2012 March 17-23; Vancouver, BC,
Canada.
Ko JS, SD Billings, AP Fernandez, CP Lanigan, RR Tubbs. Fully Automated Dual ISH
(DDISH) Staining for MYC Amplification: a Diagnostic Tool for Discriminating Secondary
Angiosarcoma. United States and Canadian Academy of Pathology 101st
Annual Meeting; 2012
March 17-23; Vancouver, BC, Canada.
Ko JS, Falzarano SM, Walker E, Streator Smith K, Klein EA, Magi-Galluzzi C. Prostate cancer
in patients older than 70 years treated by radical prostatectomy: clinicopathologic analysis and
Jennifer Ko 6/10

7.
outcome. United States and Canadian Academy of Pathology 101st
Annual Meeting; 2012
March 17-23; Vancouver, BC, Canada.
Ko J, Procop G, Bhaskaran A, Desai H, McMahon J, Farver C. Nodular Pulmonary Granuloma
Formation by Acanthamoeba in a Patient Receiving Rituximab Therapy. College of American
Pathologists Annual Meeting; 2011 September 11-14; Grapevine, TX.
Ko J, Rayman P, Cohen P, Nolan B, Biswas S, Biswas K, Tannenbaum C, Lindner D, Borden E,
Rini B, and Finke J. Tumor-derived Products Dynamically Convert Neutrophils into CD15+
Myeloid-Derived Suppressor Cells via Sunitinib-Sensitive and Insensitive Mechanisms.
Regulatory Myeloid Cells, an International Immunopharmacology Conference; 2010 October 21-
24; Washington DC.
Ko J, Rayman P, Jacobs B, Ireland J, Lindner D, Finke J, Borden E. Dual Mechanistic Function
of MDSC Subsets in Melanoma. American Society of Clinical Oncology Annual Meeting; 2010
June 4-8; Chicago, IL.
Ko J, Rini B, Ireland J, Rayman P, Cohen P, Finke J. Sunitinib-mediated MDSC inhibition
reverses tumor-induced immune suppression. American Association for Cancer Research 100th
Annual Meeting; 2009 April 18-22; Denver, CO.
Biswas K, Chahlavi A, Biswas S, Ko J, Rayman P, Das T, Sa G, Tannenbaum C, Vogelbaum M,
Finke J. Glioblastoma-derived gangliosides induce T cell death by activating the caspase
cascade and degradation of the anti-apoptotic RelA and Bcl2. American Association for Cancer
Research 100th Annual Meeting; 2009 April 18-22; Denver, CO.
Ko J, Salas R, Ireland J, Rayman P, Rini B, Finke J, Cohen P. Myeloid-specific immune cell
impact of sunitinib reverses tumor-induced immune suppression. Molecular Targets for Cancer
Therapy: 5th
Biennial Meeting; 2009 March 12-15; Moffitt Cancer Center, Clearwater Beach,
Florida.
Rayman P, Ko J, Cohen P, Finke J. Tumor-derived products dynamically activate CD15+
subset of myeloid-derived suppressor cells. Molecular Targets for Cancer Therapy: 5th
Biennial
Meeting; 2009 March 12-15; Moffitt Cancer Center, Clearwater Beach, Florida.
Ko J, Zea A, Rini B, Ireland J, Elson P, Cohen P, Golshayan A, Rayman P, Wood L, Garcia J,
Driecer R, Bukowski R, Finke J. Sunitinib mediates reversal of myeloid-derived suppressor cell
accumulation in metastatic renal cell carcinoma patients. American Association for Cancer
Research Annual Meeting; 2008 April 12-16; San Diego, CA.
Salas R, Ireland J, Ko J, Elson P, Garcia J, Wood L, Bukowski R, Rini B, Finke J. Immune cell
changes in the peripheral blood of metastatic renal cell carcinoma patients treated with sunitinib
or temsirolimus. American Society of Clinical Oncology Annual Meeting; 2008 May 30-June 3;
Chicago, Il.
George S, Rayman P, Biswas S, Garcia J, Ko J, Wood L, Smith-Williams T, Elson P, Driecer R,
Rini B, Bukowski R, Finke J. Expression of Flt3 and VEGFR1 on myeloid-derived suppressor
cells in renal cell carcinoma patients. American Society of Clinical Oncology Annual Meeting;
2008 May 30-June 3; Chicago, Il.
Jennifer Ko 7/10

8.
Ko J, Biswas S, Biswas K, Finke J, Tannenbaum C. Gangliosides derived from renal and brain
tumor lines inhibit T lymphocyte proliferation and dendritic cell maturation. American
Association for Cancer Research Annual Meeting; 2006 April 1-5; Washington DC.
Oral Presentations/Invited Speaker
Oral Platform Presentation, “Worse outcome in melanoma patients recently pregnant: decreased
T-cell programmed death receptor-1 (PD-1) expression in primary tumors suggests immune
ignorance,” World Congress of Dermatology 23rd Annual Meeting, June 8th-13th,Vancouver,
Canada.
Oral Platform Presentation, “Cutaneous Manifestations in Inflammatory Bowel Disease: A
Single Institutional Study of 209 Patients.” United States and Canadian Academy of Pathology
Annual Meeting; 2015 March 21-27; Boston, MA, USA.
Oral Platform Presentation, “Worse outcome in melanoma patients recently pregnant: decreased
T-cell programmed death receptor-1 (PD-1) expression in primary tumors suggests immune
ignorance,” The American Society of Dermatopathology 51st
Annual Meeting, November 8,
2014, Chicago, Il.
Oral Presentation, Duel in Dermatopathology, “Menkes disease: a clinical case and review,” The
American Society of Dermatopathology 50th Annual Meeting, October 10, 2013, Washington
DC.
Faculty Presentation, “What You Need to Know about Innate Immunity,” Society for
Immunotherapy of Cancer (SITC) CME Course- Advances in Cancer Immunotherapy: from
Bench to Bedside and Back. October 4, 2013, Cleveland, Ohio.
Oral Presentation, Duel in Dermatopathology, “Sweet’s Syndrome in the setting of AML
containing a Morphologic Mimicker of Cryptococcus,” The American Society of
Dermatopathology 48th
Annual Meeting, October 20, 2011, Seattle, WA.
Oral Presentation, “Tumor-derived Products dynamically Convert Neutrophils into n-MDSC via
Sunitinib-Sensitive and Insensitive Mechanisms,” International Immunopharmacology
Conference on Regulatory Myeloid Cells, October 24, 2010, Washington DC.
Invited Speaker, “Myeloid Derived Suppressor Cells in Cancer Progression; Promotion of T-cell
Immunity by the TKI Sunitinib” Taussig Cancer Institute GU Cancers Preceptorship: Renal Cell
Carcinoma: Pathology, Diagnosis and Treatment, September 14, 2010, Cleveland Clinic,
Cleveland, Ohio.
Invited Speaker, “Mechanisms of Myeloid-Derived Suppressor Cell Accumulation in Cancer and
Susceptibility to Reversal by Sunitinib,” Translational Hematology and Oncology Research
Lecture Series, June 1, 2010, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH.
Oral Presentation, “Sunitinib mediated inhibition of myeloid-derived suppressor cells reverses
tumor-induced immune suppression.” American Association for Cancer Research 100th
Annual
Meeting. April 19, 2009, Denver, CO.
Jennifer Ko 8/10

9.
Teaching Seminars/Lectures
Seminar, “Contemporary Issues in the Management of Merkel Cell Carcinoma” Pathology and
Laboratory Medicine Grand Rounds, February 26, 2015, Cleveland Clinic, Cleveland, OH.
Seminar, “Tumor Immunology…You’ve come a long way baby!” Pathology and Laboratory
Medicine Grand Rounds, October 24, 2013, Cleveland Clinic, Cleveland, OH.
Seminar, “The Role of Th17 in Cancer” Continuing Education Lecture Series, August 1, 2013,
Cleveland Clinic, Cleveland, OH.
Seminar, “The Immunoscore: Coming to a Tumor Classification System Near You,” Pathology
and Laboratory Medicine, June 19, 2013, Cleveland Clinic, Cleveland, OH.
Seminar, “Laboratory Administration: Quality and Compliance,” Continuing Education Lecture
Series, June 28, 2012, Cleveland Clinic, Cleveland, OH.
Seminar, “Cutaneous Fungal Infections, from Bedside to Bench,” Continuing Education Lecture
Series, April 6, 2012, Cleveland Clinic, Cleveland, OH.
Seminar, “B-RAF Testing in Malignant Melanoma,” Pathology and Laboratory Medicine Grand
Rounds, February 23, 2012, Cleveland Clinic, Cleveland, OH.
Seminar, “Myeloid-Derived Suppressor Cells in Cancer Progression; Promotion of T-Cell
Immunity by the Tyrosine Kinase Inhibitor Sunitinib.” Pathology and Laboratory Medicine
Grand Rounds, June 10, 2011, Cleveland Clinic, Cleveland, OH.
Medical student lectures, “Hematemesis and Dysphagia, Pathologic Correlation,” Clinical
Rounds, 2011-2012, Cleveland Clinic Lerner College of Medicine, Cleveland, OH.
Seminar, “Mechanisms of Myeloid-Derived Suppressor Cell Accumulation in Cancer and
Susceptibility to Reversal by Sunitinib.” Case Western Reserve University Pathology and
Immunology Lecture Series, October 12, 2009, CWRU, Cleveland, OH.
Seminar, “Myeloid-derived suppressor cells and anti-angiogenic therapy.” Case Western Reserve
University Pathology and Immunology Lecture Series, January 21, 2009, CWRU, Cleveland,
OH.
Seminar, “Myeloid-derived suppressor cells in renal cell carcinoma.” Immunology Lecture
Series, October 1. 2008, Lerner Research Institute, Department of Immunology, Cleveland, OH.
Seminar, “Tumor-derived gangliosides suppress T cell function.” Case Western Reserve
University Pathology and Immunology Lecture Series, May 11, 2007, CWRU, Cleveland, OH.
Publications Reviewed and Other Experience
Formulation of Grants:
Jennifer Ko 9/10

10.
Pfizer Grant – “Defining the mechanisms by which sunitinib regulates T regulatory and myeloid-
derived suppressor cells in renal cell carcinoma patients and improves T cell immunity.” Direct
cost 120,000/year.
NIH R01 – “Sunitinib modulation of cancer immunotherapy.” Direct cost 350,000/year.
Research Program Council Grant- “Define the expression of Programmed Death (PD)-1 and
Programmed Death Ligand (PD-L1) complex on myeloid and T cells in the blood and tumor of
patients with renal cell carcinoma and assess the impact of TKI on their expression” Direct cost
20,000/year
Review Manuscripts: Journal of Immunology, Clinical Cancer Research, Journal of Interferon
and Cytokine Research, International Immunopharmocology, and Journal of Cutaneous
Pathology.
Internal Grant Reviewer, Research Program Council
Professional Memberships
• American Society of Dermatopathology (2012-present)
• College of American Pathologists (2011-present)
• American Society for Clinical Pathology (2011-present)
• United States and Canadian Academy of Pathology (2011-present)
• Association for Molecular Pathology (2011-present)
• Cleveland Society of Pathologist (2010-present)
• Society for Immunotherapy of Cancer (2013-present)
Jennifer Ko 10/10